Instylla Wins FDA Approval for Embrace Bleeding Device
BURLINGTON, Massachusetts, October 29, 2026 Instylla, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BURLINGTON, Massachusetts, October 29, 2026 Instylla, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved...
